针对前列腺特异性膜抗原（PSMA）的正电子发射断层扫描（PET）成为临床和试验中前列腺癌患者分期和复发性评估的基准成像工具。前列腺癌分子影像标准评估（PROMISE）标准将PSMA-PET作为全身分期（分子成像TNM分期，标记为miTNM分期）框架，描述前列腺癌在PSMA-PET上的疾病范围。为了创建一个全面的和集成的PSMA-PET图像解读和报告框架，我们提出了PROMISE V2框架，它整合了更新的miTNM系统、更好的局部疾病评估和略微修改的PSMA表达评分用于临床例行工作。我们增加了一个响应监控框架，定义了记录定性和定量参数以进行临床试验中的纵向评估。我们在当前临床研究和前瞻性试验中提供了全面的文献综述，PROMISE变量与生存呈明显关联。PSMA表达评分在几项试验中得到了应用，低PSMA表达评分是177Lu-PSMA放射性配体治疗后总生存率的负面预测因素。用于治疗反应评估的提议成像参数既可以根据PSMA-PET进展（PPP）或PSMA-PET /计算机体层摄影反应评估标准（RECIP）框架进行测量，也可用于未来的响应标准。PROMISE V2提供了临床例行工作和研究的标准化疾病范围报告。在临床试验中记录的参数有助于客观评估治疗反应。前列腺特异性膜抗原（PSMA）靶向正电子发射断层扫描（PET）已成为前列腺癌的标准成像检查，我们提出了一个全面的框架，用于分析和报告PSMA-PET检查结果，将改善成像专家和泌尿肿瘤学家之间的沟通。版权 ©2023作者。Elsevier B.V. 发布。保留所有权利。

Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria have been proposed as a framework for whole-body staging (molecular imaging TNM staging, denoted miTNM staging) to describe the prostate cancer disease extent on PSMA-PET.To create a comprehensive and integrated framework for PSMA-PET image interpretation and reporting.We propose the PROMISE V2 framework, which integrates an updated miTNM system, improved assessment of local disease, and a slightly modified PSMA-expression score for clinical routine. We have added a response monitoring framework defining qualitative and quantitative parameters to be recorded for a longitudinal assessment in clinical trials.We provide a comprehensive literature review on the current use of the PROMISE framework in clinical research and prospective trials. PROMISE variables demonstrate a clear association with survival. PSMA expression assessed by the PSMA-expression score was used in several trials, and a low PSMA-expression score is a negative prognosticator of overall survival after 177Lu-PSMA radioligand therapy. The proposed imaging parameters recorded for response assessment in clinical trials can be utilized to determine response according to PSMA-PET progression (PPP) or Response Evaluation Criteria in PSMA-PET/Computed Tomography (RECIP) frameworks, but also future response criteria.PROMISE V2 offers standardized reporting of disease extent for clinical routine and research. Parameters recorded within clinical trials facilitate objective response assessment.Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) has become a standard imaging examination for prostate cancer. We propose a comprehensive framework for the analysis and reporting of PSMA-PET findings that will improve the communication between imaging experts and uro-oncologists.Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.